Oral Pharmacotherapy for Male Sexual Dysfunction

1. Front Matter

   Pages i-xii

   PDF

2. Physiology and Pharmacology of Erectile Dysfunction

   • Rafael Carrion, Derek Bochinski, Nadeem Rahman, Tom Lue

   Pages 1-24

3. Epidemiology of Erectile Dysfunction

   • Jonathan D. Schiff, John P. Mulhall

   Pages 25-42

4. Pharmacology of Phosphodiesterase Inhibitors

   • Erwin Bischoff

   Pages 43-63

5. Sildenafil Citrate, the Classic PDE5 Inhibitor

   • Harin Padma-Nathan

   Pages 65-83

6. Tadalafil

   • Culley C. Carson III

   Pages 85-107

7. Vardenafil Clinical Trials Experience

   • Ajay Nehra

   Pages 109-148

8. Erectile Dysfunction Assessment and Management in Primary Care Practice

   • Louis Kuritzky, Martin Miner

   Pages 149-183

9. When to Refer the Patient With Erectile Dysfunction to a Specialist

   • Ira D. Sharlip

   Pages 185-197

10. Erectile Dysfunction

    • Thorsten Reffelmann, Robert A. Kloner

    Pages 199-220

11. Is Diabetic Erectile Dysfunction More Difficult to Treat?

    • Pierre Theuma, Vivian A. Fonseca

    Pages 221-236

12. Depression and Antidepressant-Associated Erectile Dysfunction

    • Raymond C. Rosen

    Pages 237-251

13. Intracavernous, Transurethral, and Topical Therapies for Erectile Dysfunction in the Era of Oral Pharmacotherapy

    • Hans-Martin A. Fritsche, Mustafa F. Usta, Wayne J. G. Hellstrom

    Pages 253-277

14. Androgen Deficiency in the Aging Male

    • Alvaro Morales, Jeremy P. W. Heaton

    Pages 279-299

15. Central Activation of Erection and Clinical Experience

    • Jeremy P. W. Heaton, Alvaro Morales, Michael A. Adams

    Pages 301-322

16. Sustaining the Cure

    • Ronald W. Lewis

    Pages 323-337

17. Prevention and Treatment of Erectile Dysfunction Utilizing Lifestyle Changes and Dietary Supplements

    • Mark A. Moyad

    Pages 339-378

18. Pharmacological Strategies in the Management of Rapid Ejaculation

    • Chris G. McMahon

    Pages 379-408

19. Sexual Dysfunction After Radical Prostatectomy and the Use of PDE-5 Inhibitors

    • Andrew R. McCullough

    Pages 409-421

20. Female Sexual Dysfunction

    • Ridwan Shabsigh, Anne R. Davis, Aristotelis G. Anastasiadis, Nawras Makhsida, Grace Yan

    Pages 423-443

For the generation that reached sexual maturity in the 1960s, the “pill” became synonymous with sexual freedom and started a sexual revolution. For women it meant freedom from the fear of pregnancy, and for men enhanced sexual opportunity. The new era of the pill has nothing to do with fertility, but everything to do with sex. The first orally effective prescr- tion drug for treating erectile dysfunction (ED) was marketed in 1998. ® Sildenafil (Viagra ) has rejuvenated the aging male veterans of the sexual revolution, forever changed the science of sexual medicine, and tra- formed society’s perspective on aging and sex. This class of drugs, known as oral phosphodiesterase inhibitors (PDE-type 5), is highly effective in the treatment of ED. Since its introduction there has been a much greater awa- ness of ED, its comorbidities, and its effects on the quality of life. In 1997, while preparing to address the Endocrine Society on the occasion of the 92nd American Urological Association meeting, I first looked at the p- clinical studies of sildenafil. I thought “this will change everything” and it clearly has—changing practice patterns in sexual medicine, and the at- tudes of patients, potential patients, and their partners. Two new PDE-type ® ® 5 inhibitors, tadalafil (Cialis ) and vardenafil (Levitra ), were first approved by the European Committee for Proprietary Medicinal Products and subsequently by the Food and Drug Administration in 2003 and 2004.

• Internist
• assessment
• patients
• primary care
• quality
• safety

• Department of Urology, Mayo Clinic College of Medicine, Jacksonville

  Gregory A. Broderick

Policies and ethics